With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era

FDA has approved olaparib (Lynparza) and rucaparib (Rubraca) to treat some men with metastatic prostate cancer. The PARP inhibitors are approved for men whose cancers have stopped responding to hormone treatment and have specific genetic alterations.

from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/3flgMVz